4//SEC Filing
Dorsey Brian 4
Accession 0001415889-24-029376
CIK 0001671858other
Filed
Dec 12, 7:00 PM ET
Accepted
Dec 13, 7:52 PM ET
Size
14.4 KB
Accession
0001415889-24-029376
Insider Transaction Report
Form 4
Dorsey Brian
Chief Operating Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-12-12−25,000→ 21,828 totalExercise: $0.64Exp: 2028-11-28→ Common Stock (25,000 underlying) - Exercise/Conversion
Common Stock
2024-12-11$0.64/sh+15,000$9,600→ 21,024 total - Exercise/Conversion
Common Stock
2024-12-12$0.64/sh+25,000$16,000→ 31,024 total - Sale
Common Stock
2024-12-12$12.30/sh−25,000$307,433→ 6,024 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-12-11−15,000→ 46,828 totalExercise: $0.64Exp: 2028-11-28→ Common Stock (15,000 underlying) - Sale
Common Stock
2024-12-11$12.43/sh−15,000$186,426→ 6,024 total
Footnotes (4)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2023.
- [F2]The weighted average sale price for the transaction report was $12.4284, and the range of prices were between $12.34 and $12.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]The weighted average sale price for the transaction report was $12.2973, and the range of prices were between $12.13 and $12.60. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F4]Immediately exercisable.
Documents
Issuer
ARS Pharmaceuticals, Inc.
CIK 0001671858
Entity typeother
Related Parties
1- filerCIK 0001380762
Filing Metadata
- Form type
- 4
- Filed
- Dec 12, 7:00 PM ET
- Accepted
- Dec 13, 7:52 PM ET
- Size
- 14.4 KB